biochimica clinica

en_US English
en_US English it_IT Italian

CONTRIBUTI SCIENTIFICI – Scientific Papers

Volume:

Biochimica Clinica, vol.47, n.4, pag 346-54

Pubblicato on-line:

September 18, 2023

DOI:

10.19186/BC_2023.066

Scarica in PDF:
Autenticazione richiesta

Contribution of Rotational Thromboelastometry (ROTEM) research parameters for the evaluation of hypercoagulability in patients with Multiple Myeloma. A pilot study

AUTORI

Ciro Miele1,2 , Piero Consorti1 , Rosaria Mormile1 , Teresa Mancino1,3 , Gaetano Mastranzo1 , Francesca Saviano1 , Francesca D’Auria1 , Luca Manfredi1 , Alessandra Vasco1,2 , Roberta della Pepa4 , Marcella Savoia1,2,3 , Cristina Mazzaccara1,2,3 , Filomena Capasso1,3
1 Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy
2 CEINGE Advanced Biotechnologies, Naples, Italy
3 Department of Integrated Activity of Laboratory Medicine and Transfusion, University of Naples "Federico II", Naples, Italy
4 Hematology Unit, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy

ABSTRACT

Introduction: hematological malignancies are associated with an increased thrombotic risk compared to solid tumors. Multiple myeloma (MM) is a hematological neoplastic disease with strong thromboembolic repercussions. In these patients the venous thromboembolism may occur during the first months of treatment with immunomodulatory drugs (IMiDs), in combination with high-dose of dexamethasone. Although IMiDs therapy improves the clinical outcome, a concomitant increase of thromboembolic manifestations are observed. Rotational thromboelastometry, provides information on the clot formation, its stabilization and dissolution, reflecting in vivo patient’s hemostasis. The aim of the study was to investigate the dynamic state of clot formation, through the evaluation of research parameters, in addition to standard ones, to best evaluate the thrombotic risk in these patients.
Methods: thirty-four MM patients and thirty-five controls were unrolled from Hematology Department of the University Hospital Federico II of Naples, Italy. To evaluate the coagulation’s dynamics status, we investigated EXTEM, INTEM and FIBTEM assays, through both standard (CT, CFT, MCF, α-angle) and research (MAXV, MAXVt, AUC) parameters, using Rotational Thromboelastometry.
Results: among the research parameters, we observed statistical significance differences between controls and patients for EXTEM (MAXV: p=0.010; MAXVt: p=0.010), for INTEM (MAXV:10 p=0.005; MAXVt: p=0.005) and for FIBTEM (MAXV: p<0.001; AUC: p<0.001) tests.
Discussion: to the best of our knowledge, this is an original study showing that research parameters can give an additional contribution to the interpretation of the hypercoagulability state in MM patients, bringing to light patients who could be at higher thrombotic risk.

BIBLIOGRAFIA

  1. Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 2016;43:676-81.
  2. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
  3. Kyle RA, Rajkumar SV. Drug therapy: Multiple myeloma. N Engl J Med 2004;351:1860-73.
  4. Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol 2022;115:762-77.
  5. Kristinsson SY, Björkholm M, Schulman S, Landgren O. Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. Semin Hematol 2011;48:46-54.
  6. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-6.
  7. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006;108:403. (Author reply at pag 404).
  8. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 2022;97:1086-107.
  9. Tafur LA, Taura P, Blasi A, Beltran J, Martinez-Palli G, Balust J, et al. Rotation thromboelastometry velocity curve predicts blood loss during liver transplantation. Br J Anaesth 2016;117:741-8.
  10. Treliński J, Misiewicz M, Robak M, Smolewski P, Chojnowski K. Assessment of rotation thromboelastometry (ROTEM) parameters in patients with multiple myeloma at diagnosis. Thromb Res 2014;133:667-70.
  11. Görlinger K, Almutawah H, Almutawaa F, Alwabari M, Alsultan Z, Almajed J, et al. The role of rotational thromboelastometry during the COVID-19 pandemic: a narrative review. Korean J Anesthesiol 2021;74:91-102.
  12. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
  13. Rajkumar SV. Multiple myeloma: Every year a new standard? Hematol Oncol 2019;37 Suppl 1:62-5.
  14. Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 2017;389:519-27.
  15. De Stefano V, Larocca A, Carpenedo M, Cavo M, Di Raimondo F, Falanga A, et al. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica 2022;107:2536-47.
  16. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-4.
  17. Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003;1:551-8.
  18. Papa ML, Capasso F, Pudore L, Torre S, Mango S, Russo V, et al. Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer. Exp Oncol 2007;29:111-5.
  19. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003;1:445-9.
  20. Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007;92:279-80.
  21. Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers (Basel) 2018;10:380.
  22. Mitrugno A, Tormoen GW, Kuhn P, McCarty OJ. The prothrombotic activity of cancer cells in the circulation. Blood Rev 2016;30:11-9.
  23. Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev 2019;33:24-32.
  24. Gidaro A, Manetti R, Delitala AP, Soloski MJ, Lambertenghi Deliliers G, Castro D, et al. Incidence of venous thromboembolism in multiple myeloma patients across different regimens: role of procoagulant microparticles and cytokine release. J Clin Med 2022;11:2720.
  25. Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 2009;145:151-63.
  26. Scalambrino E, Padovan L, Clerici M, Chantarangkul V, Biliou S, Peyvandi F, et al. Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTem(R) device. Thromb Res 2018;172:139-41.
  27. Sarfraz H, Anand K, Liu S, Shah S. Multiple myeloma with concurrent immune thrombocytopenic purpura. Ecancermedicalscience 2020;14:1012.
  28. Kamińska J, Koper OM, Mantur M, Matowicka-Karna J, Sawicka-Powierza J, Sokołowski J, et al. Does thrombopoiesis in multiple myeloma patients depend on the stage of the disease?  Adv Med Sci 2014;59:166-71.
  29. Minnema MC, Fijnheer R, De Groot PG, Lokhorst HM. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.  J Thromb Haemost 2003;1:445-9.
  30. Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007;92:279-80.
  31. Fotiou D, Gavriatopoulou M, Terpos E. Multiple Myeloma and Thrombosis: prophylaxis and risk prediction tools. Cancers (Basel) 2020;12:191.
  32. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003;29:275-81.
  33. Tripodi A, Chantarangkul V, Gianniello F, Clerici M, Lemma L, Padovan L, et al. Global coagulation in myeloproliferative eoplasms. Ann Hematol 2013;92:1633-9.
  34. Lang T, Bauters A, Braun SL, Pötzsch B, von Pape KW, Kolde HJ, et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 2005;16:301-10.
  35. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23.
  36. Chalayer E, Tardy-Poncet B, Montmartin A, Boussoualim K, Genthon A, Tardy B. Effect of heparin thromboprophylaxis on thrombin generation in multiple myeloma patients. Br J Haematol 2019;186:337-9.
  37. Dargaud Y, Fouassier M, Bordet JC, Ducastelle-Lepretre S, Dumontet C, Moreau P, et al. The challenge of myeloma-related thromboembolic disease: can thrombin generation assay help physicians to better predict the thromboembolic risk and personalize anti-thrombotic prophylaxis? Leuk Lymphoma 2019;60:2572-5.
  38. Akay OM. The double hazard of bleeding and thrombosis in hemostasis from a clinical point of view: a global assessment by rotational thromboelastometry (ROTEM). Clin Appl Thromb Hemost 2018;24:850-8.
  39. Davies NA, Harrison NK, Sabra A, Lawrence MJ, Noble S, Davidson SJ, et al. Application of ROTEM to assess hypercoagulability in patients with lung cancer. Thromb Res 2015;135:1075-80.